DGIST announced that Professor Kyung-in Jang's research team from the Department of Robotics Engineering succeeded in developing bio-signal measuring electrodes that can be mounted on Internet of ...
Q32 Bio (QTTB) announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart, or ADX-914, which identified encouraging clinical activity in patients with ...
-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very ...
-- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology ...
Combining bio-signaling innovation with sustainable practices to support wellness in electronic-heavy environments. KAOHSIUNG, KAOHSIUNG, TAIWAN, September 19, 2025 ...
On Wednesday, Q32 Bio Inc. (NASDAQ:QTTB) revealed topline results from the SIGNAL-AA Phase 2a signal finding trial evaluating bempikibart (ADX-914) for alopecia areata (AA). The company plans to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback